DigestRedComo funciona
Red
/
Empresas
Bo
No verificado

Boehringer Ingelheim Limited

Sobre qué escribimos

Anuncios brevesFarmacéuticaGestión empresarial/Administración de EmpresasMedicina Salud BienestarPublicidad/Marketing/Medios de comunicación/Comunicación

47 Comunicados de prensa

Ver todos los comunicados de prensa
29/04/2026
Farmacéutica
Medicina Salud Bienestar
Boehringer Ingelheim and Eko Health Inc. launch new AI-based solution that detects heart murmurs in dogs
Fuente
Boehringer Ingelheim Limited
Editor
GLOBENEWSWIRE
1.00
0
27/04/2026
Farmacéutica
Medicina Salud Bienestar
Boehringer Ingelheim’s novel glucagon/GLP-1 dual agonist survodutide achieved significant weight loss of 16.6% delivering meaningful metabolic improvement in people with obesity or overweight in Phase III trial
Fuente
Boehringer Ingelheim Limited
Editor
GLOBENEWSWIRE
1.00
0
20/04/2026
Farmacéutica
Medicina Salud Bienestar
Boehringer Ingelheim expands investment in computational innovation with new AI Accelerator in UK’s Knowledge Quarter
Fuente
Boehringer Ingelheim Limited
Editor
GLOBENEWSWIRE
1.00
0
15/04/2026
Farmacéutica
Medicina Salud Bienestar
Boehringer Ingelheim and Zai Lab announce Collaboration on DLL3‑targeting T‑Cell Engager and ADC Combination in Small Cell Lung Cancer and Other Neuroendocrine Carcinomas
Fuente
Boehringer Ingelheim Limited
Editor
GLOBENEWSWIRE
1.00
0
13/04/2026
Farmacéutica
Medicina Salud Bienestar
Boehringer Ingelheim introduces LENZELTA®: A new vaccine advancing mastitis prevention in dairy cows
Fuente
Boehringer Ingelheim Limited
Editor
GLOBENEWSWIRE
1.00
0
09/04/2026
Farmacéutica
Publicidad/Marketing/Medios de comunicación/Comunicación
Boehringer Ingelheim to evaluate innovative combination of DLL3‑targeting T‑cell engager plus PD‑L1/VEGF‑A bispecific antibody in small cell lung cancer
Fuente
Boehringer Ingelheim Limited
Editor
GLOBENEWSWIRE
1.00
0
09/04/2026
Farmacéutica
Medicina Salud Bienestar
Ecuador Free of Rabies project accelerates progress toward eliminating dog-mediated rabies supported by Boehringer Ingelheim’s Stop Rabies program
Fuente
Boehringer Ingelheim Limited
Editor
GLOBENEWSWIRE
1.00
0
24/03/2026
Farmacéutica
Medicina Salud Bienestar
Boehringer Ingelheim delivers on late-stage pipeline with two key launches, grows sales by 7.3%* in a successful 2025
Fuente
Boehringer Ingelheim Limited
Editor
GLOBENEWSWIRE
1.00
0
26/02/2026
Farmacéutica
Medicina Salud Bienestar
FDA approves HERNEXEOS®, the first targeted therapy for adults with HER2-mutant advanced NSCLC as an initial treatment option
Fuente
Boehringer Ingelheim Limited
Editor
GLOBENEWSWIRE
1.00
0
26/02/2026
Farmacéutica
Publicidad/Marketing/Medios de comunicación/Comunicación
Boehringer Ingelheim licenses novel oral therapeutics program for immune diseases from Sitryx Therapeutics
Fuente
Boehringer Ingelheim Limited
Editor
GLOBENEWSWIRE
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0